BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) concerning the Company’s and its officers’ possible violations of federal securities laws.
The investigation focuses on the allegedly misleading statements found in the Company’s public statements and SEC filings which failed to disclose, among other things, that: (i) Revance had not commenced a Phase 3 clinical trial of RT001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; and (ii) Revance did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial. When the true details entered the market, the Company’s share price declined sharply and investors suffered damages.
If you purchased Revance securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.